Every material Form 8-K SBC Medical Group Holdings Inc has filed with the SEC since May 20, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
SBC Medical Group Holdings reported second-quarter 2026 revenue of $49 million, up 13% year over year, and net income attributable to the company of $11 million, up 335%. Over the first half, revenue rose 2% to $92 million, but net income attributable to the company fell 8% to $22 million, so the quarterly gain does not yet show up in the six-month totals.
Q2 2026 basic EPS was $0.10, versus $0.02 in Q2 2025; first-half basic EPS was $0.21, down 9% from $0.23.
Q2 2026 Adjusted EBITDA was $20 million, up 32%, with an Adjusted EBITDA margin of 41%.
The company said its fee revisions could add approximately $15 million in annual service fees if their impact is realized for a full year.
As of June 30, 2026, cash and cash equivalents were $184 million; the company also posted investor presentations on August 13, 2026.
SBC Medical received a Nasdaq notice that it no longer meets independent director and audit committee rules after Mike Sayama chose not to seek re-election. Stockholders also approved charter amendments and the board adopted amended bylaws, including a majority-vote resignation policy for uncontested director elections. The company says the notice has no immediate effect on its listing, but it must restore compliance within the cure period.
Nasdaq notice received July 10, 2026; board has four members, two of them independent, and the audit committee has two independent directors
Cure period ends at the earlier of the next annual meeting or July 9, 2027, or January 5, 2027 if the next annual meeting is held before that date
Restated charter effective July 9, 2026; amended and restated bylaws adopted July 8, 2026
Stockholders elected four directors and ratified MaloneBailey, LLP as auditor for fiscal 2026 with 93,954,650 votes for
Independent director Mike Sayama notified SBC Medical Group on May 14, 2026, that he will not seek re-election at the 2026 Annual Meeting of Stockholders. The board reduced its size to four members effective before the polls open at that meeting, and it plans to search for a fifth independent director to join after the meeting. The filing says Mr. Sayama's decision did not stem from any disagreement with the company, its management, or the board on operations, policies or practices.
Mike Sayama, an independent director, notified the company on May 14, 2026 that he will not seek re-election.
Board size will be reduced to four members, effective immediately before the polls open at the 2026 AGM.
The board is searching for a fifth independent director; it intends to appoint that person to the nominating and governance, compensation and audit committees, replacing Mr. Sayama's committee seats.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every SBC Medical Group Holdings Inc filing is on SEC EDGAR ↗. 8-K briefs of other companies →